Anji: a new wrinkle on asset-centric development

Using a business model centering on joint ventures, three-year-old Anji will test whether its “dynamic equity” in-licensing approach will create sufficient value to appeal to more biopharma programs’ originators.

Anji Pharmaceuticals Inc. said Tuesday it had raised $70 million from a single investor, China-based CR Capital, that will help it fund two clinical programs. Anji is advancing ANJ900, a gut-targeted formulation of metformin for Type II diabetes, in the Phase III DREAM-T2D study; and ANJ908, a DGAT1 inhibitor in Phase II testing for chronic idiopathic constipation...